Nasopharyngeal carcinoma in american children: Epstein-Barr virus-specific antibody titers and prognosis

1982 ◽  
Vol 29 (2) ◽  
pp. 209-212 ◽  
Author(s):  
Robert F. Naegele ◽  
John Champion ◽  
Sharon Murphy ◽  
Gertrude Henle ◽  
Werner Henle
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Specific Antibody ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Virus Specific Antibody ◽  
Antibody Titers ◽  
Epstein Barr ◽  
American Children

Application of Epstein-Barr Virus Serology to the Diagnosis and Staging of North American Patients with Nasopharyngeal Carcinoma

1983 ◽  
Vol 91 (3) ◽  
pp. 255-262 ◽  
Author(s):  
H. Bryan Neel ◽  
Gary R. Pearson ◽  
Louis H. Weiland ◽  
William F. Taylor ◽  
Helmut H. Goepfert ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
North American ◽  
Epstein Barr Virus ◽  
Geometric Mean ◽  
World Health ◽  
Barr Virus ◽  
Staging Systems ◽  
Antibody Titers ◽  
Epstein Barr

From 1978 to 1981, 151 patients with nasopharyngeal carcinoma (NPC) were enrolled in a prospective, collaborative study of North American patients, most of them white. Thirty-seven had World Health Organization (WHO) type 1 tumors, and 114 had WHO types 2 and 3 tumors. The anti-Epstein-Barr virus (EBV) profile of elevated antibody titers directed against viral capsid antigen and early antigen was seen in 85% of the patients with WHO types 2 and 3 tumors but in only 16% of the patients with WHO type 1 tumors. Geometric mean titers tended to be higher in higher stages of the disease in several staging systems. Low antibody-dependent cellular cytotoxicity at diagnosis appears to reflect a poorer prognosis, and the determination of antibody titers by this assay may prove to be useful for identifying persons in whom recurrent disease is likely to develop after conventional therapy. Anti-EBV titers can aid in diagnosis and treatment planning in patients with NPC, particularly those with occult primary NPC.

Immunologic Detection of Occult Primary Cancer of the Head and Neck

1981 ◽  
Vol 89 (2) ◽  
pp. 230-234 ◽  
Author(s):  
H. Bryan Neel ◽  
Gary R. Pearson ◽  
Louis H. Weiland ◽  
William F. Taylor ◽  
Helmuth H. Goepfert
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Head And Neck ◽  
Epstein Barr Virus ◽  
Testing Procedure ◽  
Primary Cancer ◽  
Diagnostic Aid ◽  
Barr Virus ◽  
Antibody Titers ◽  
Epstein Barr ◽  
Obvious Source

Because antibody titers against Epstein-Barr virus (EBV) antigens often are elevated in patients with active undifferentiated and nonkeratinizing nasopharyngeal carcinoma, anti-EBV serologic tests have been applied as a diagnostic aid in patients who have metastatic lymphadenopathy in the neck without an obvious source. In this study of 44 patients, the serologic testing procedure proved useful in identifying six patients with nasopharyngeal carcinoma that was initially occult but was eventually confirmed by biopsy.

scholarly journals Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Massimiliano Castellazzi ◽  
Serena Delbue ◽  
Francesca Elia ◽  
Matteo Gastaldi ◽  
Diego Franciotta ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Specific Antibody ◽  
Epstein Barr Virus ◽  
Serum Levels ◽  
Nuclear Antigen ◽  
Barr Virus ◽  
Natalizumab Treatment ◽  
Virus Specific Antibody ◽  
Epstein Barr ◽  
Multiple Sclerosis Patients

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Natalizumab, a humanized anti-α4 integrin monoclonal antibody, is a highly effective treatment approved for MS. An association between MS and an exposure to Epstein-Barr Virus (EBV) sustained by the levels of antiviral capsid antigen (VCA) and anti-Epstein-Barr nuclear antigen-1 (EBNA-1) IgG has been described. Our goal was to verify the utility of EBV-specific IgG as a marker in Natalizumab treated MS. Twenty patients (17 female and 3 male) in treatment with Natalizumab were enrolled. Serum levels of anti-VCA and anti-EBNA-1 IgG were determined and expressed as arbitrary units (AU) before treatment and every three months for 21 months of therapy. Anti-VCA IgG levels were increased at the 15th month (235410 ± 196712 AU) comparing with the 3rd (98146 ± 47145 AU) and the 6th (109866 ± 52270 AU) months of therapyp<0.05. No significant differences were found for serum anti-EBNA-1 IgG levels. Our data indicate that a transient, self-limited, EBV reactivation can occur in MS during Natalizumab therapy but our results do not support the use of serum EBV-specific antibody levels as biomarkers for monitoring therapeutic response to Natalizumab in the course of MS.

scholarly journals Evaluation of a Multianalyte Profiling Assay and an Enzyme-Linked Immunosorbent Assay for Serological Examination of Epstein-Barr Virus-Specific Antibody Responses in Diagnosis of Nasopharyngeal Carcinoma

2008 ◽  
Vol 15 (11) ◽  
pp. 1684-1688 ◽  
Author(s):  
Ai-Di Gu ◽  
Hao-Yuan Mo ◽  
Yan-Bo Xie ◽  
Rou-Jun Peng ◽  
Jin-Xin Bei ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Immunosorbent Assay ◽  
Specific Antibody ◽  
Epstein Barr Virus ◽  
Antibody Responses ◽  
Nuclear Antigen ◽  
Enzyme Linked Immunosorbent Assay ◽  
Barr Virus ◽  
Serological Examination ◽  
Epstein Barr

ABSTRACT Assessment of antibody responses to Epstein-Barr virus (EBV) antigens has been used to assist in nasopharyngeal carcinoma (NPC) diagnosis by several methods. In this study, we evaluated an in-house Luminex multianalyte profiling (xMAP) technology and commercial enzyme-linked immunosorbent assay (ELISA) kits for serological examination of EBV-specific antibody responses in 135 NPC patients and 130 healthy controls. Four EBV biomarkers were measured: immunoglobulin A (IgA) against viral capsid antigen (VCA), EBV nuclear antigen 1 (EBNA1), diffused early antigen (EA-D), and IgG against EA-D. The sensitivities and specificities of the four markers ranged between 71.5 and 90% for xMAP assays and 80 and 92% for ELISA. Logistic regression analysis revealed that the combined markers in the xMAP assay had overall sensitivity and specificity values of 82% and 92%, respectively. The correlation coefficient (r) values for the xMAP assay and ELISA were lowest for IgA-VCA (0.468) and highest for IgA-EBNA1 (0.846); for IgA-EA-D and IgG-EA-D, the r values were 0.719 and 0.798, respectively. The concordances of the two methods for NPC discrimination were good (79 to 88%). Our results suggest that both the xMAP assay and ELISA are satisfactory for EBV antibody evaluation when multiple antigens are included.

Sign in / Sign up

Export Citation Format

Share Document